The newly identified glutaminase (GLSs) inhibitors selenadiazole-derivatives CPD20 and CPD23 exhibited accumulated uptake in tumor cells and improved anti-cancer activity in CRC cells [266]. Here, GLS is linked to colorectal carcinoma.